RA’ANANA, Israel and NEW YORK, Aug. 14, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced financial results for the second quarter ended June 30, 2017 and provided an overview of the Company’s recent developments.
“UroGen has a clear vision and business strategy to become a leader in the treatment of urothelial cancers and other urological pathologies,” said Ron Bentsur, Chief Executive Officer of UroGen. “This has been a highly productive period for the Company, highlighted by the recent closing of our initial public offering and commencement of patient enrolment in our open label Phase 3 OLYMPUS pivotal trial of MitoGel™ for the treatment of UTUC, a condition for which there are no FDA approved drugs. We look forward to building upon our positive momentum throughout the rest of the year and into 2018.”
“UroGen has a clear vision and business strategy to become a leader in the treatment of urothelial cancers and other urological pathologies,” said Ron Bentsur, Chief Executive Officer of UroGen. “This has been a highly productive period for the Company, highlighted by the recent closing of our initial public offering and commencement of patient enrolment in our open label Phase 3 OLYMPUS pivotal trial of MitoGel™ for the treatment of UTUC, a condition for which there are no FDA approved drugs. We look forward to building upon our positive momentum throughout the rest of the year and into 2018.”
